Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Clinical Stage III Cutaneous Melanoma AJCC V8

Clinical Stage III Cutaneous Melanoma AJCC V8

14

Pipeline Programs↗

11

Active Trials↗

7

Companies Involved↗

Clinical Stage III Cutaneous Melanoma AJCC v8 is an emerging landscape with 14 programs across 7 companies. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

6/100

Mech. Concentration

17/100

Completion Rate

0/100

Attrition Rate

8/100

Pipeline

Programs by Phase

Preclinical2

Sirolimus

Prism Pharmaceuticals

Navitoclax

AbbVie

Phase 12

Prednisone

Roxane Laboratories

Tacrolimus

Veloxis Pharmaceuticals

Phase 23

Atezolizumab

Roche

Bevacizumab

Roche

Cabozantinib

Bristol-Myers Squibb

Phase 37

Nivolumab

Bristol-Myers Squibb

Dabrafenib Mesylate

National Cancer Institute (NCI)

Ipilimumab

Bristol-Myers Squibb

Trametinib Dimethyl Sulfoxide

Novartis

Pembrolizumab

Merck & Co.

Approved

No programs

Analysis

Modality Breakdown

12programs

Small molecule758%

Monoclonal antibody542%

Modality classified for 86% of 14 pipeline programs.

Analysis

Trial Status

12

clinical trials

Active, not recruiting8 · 67%

Recruiting2 · 17%

Not yet recruiting1 · 8%

Terminated1 · 8%

Clinical Trials

Trial Activity

12 trials

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05136196·150 enrolled

A Phase 2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous Cancers

Recruiting·National Cancer Institute (NCI)·Preclinical·NCT05896839·16 enrolled

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

Active, not recruiting·MM.D. Anderson Cancer Center·N/A·NCT04990726·126 enrolled

A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04940299·35 enrolled

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02506153·1,301 enrolled

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial

Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02224781·267 enrolled

Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)

Active, not recruiting·National Cancer Institute (NCI)·Preclinical·NCT01989585·75 enrolled

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Active, not recruiting·FF. Stephen Hodi, MD·Phase 2·NCT04356729·30 enrolled

Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination With CMP-001 in Patients With Operable Melanoma: Efficacy and Biomarker Study

Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT04708418·60 enrolled

Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT03816332·12 enrolled

AFFORD IO: A Phase 2 Trial of Low Dose, Reduced Frequency Nivolumab (Anti-PD-1 Antibody) in Patients With Unresectable or Metastatic Cancer

Not yet recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT07576725·50 enrolled

A Phase II Study to Evaluate the Safety and Efficacy of Rigosertib (ON 01910) Plus Pembrolizumab in Patients With Metastatic Melanoma Refractory to Immune Checkpoint Blockade

Terminated·VVanderbilt-Ingram Cancer Center·Phase 2·NCT05764395·7 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)